Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALDOB
REST API REST API
Homo sapiens
ALDOB is differentially expressed in 234 experiments: 96 organism parts: liver, kidney, ... (94 more);, 198 disease states: normal, colon carcinoma, ... (196 more);, 44 cell types 222 cell lines 26 compound treatments and 72 other conditions.
Orthologs D3ZHF3_RAT (Rattus norvegicus)   Aldob (Mus musculus)   F6PP44_CIOIN (Ciona intestinalis)   A5PK73_BOVIN (Bos taurus)   ALDOB_CHICK (Gallus gallus)   F6PP38_CIOIN (Ciona intestinalis)   aldob (Danio rerio)   CG5432 (Drosophila melanogaster)   Ald (Drosophila melanogaster)   aldob (Xenopus laevis)   ALDOB (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, glucose metabolic process, response to copper ion, protein binding, cytoplasm, lysosome, gluconeogenesis, NADH oxidation, response to starvation, glycolysis, identical protein binding, lyase activity, response to cAMP, microsome, microtubule organizing center, vacuole, nucleus, response to zinc ion, fructose-bisphosphate aldolase activity, carbohydrate metabolic process, response to drug, fructose metabolic process, perinuclear region of cytoplasm, cytoskeletal protein binding, response to carbohydrate stimulus, cellular response to insulin stimulus, ATPase binding, response to interleukin-6, phosphatidylcholine binding, cellular response to extracellular stimulus, fructose 1,6-bisphosphate metabolic process, smooth endoplasmic reticulum membrane, positive regulation of ATPase activity, fructose binding, response to amino acid stimulus, response to peptide hormone stimulus, centriolar satellite, rough endoplasmic reticulum membrane, liver development, vacuolar proton-transporting V-type ATPase complex assembly, response to glucocorticoid stimulus, response to fructose stimulus, response to organic cyclic compound, fructose catabolic process
InterPro Term Aldolase_I
UniProt Accession P05062, C9J4K3, Q5T7D5
Gene-Disease Assocation FRUCTOSE INTOLERANCE, HEREDITARY
Search EB-eye ENSG00000136872
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-2361, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, E-MTAB-62, ... (21 experiments)

Factor Value U/D Experiments
BT474
2
E-MEXP-440, E-MTAB-62
MCF-7
2
E-GEOD-5823, E-GEOD-20081
PC3
2
E-GEOD-5258, E-MEXP-2034
SW480
2
E-MEXP-1014, E-MTAB-37
RWPE1
1
E-MTAB-37
SKNFI
1
E-MTAB-37
216 more value(s).


Cell type

studied in E-GEOD-22373, E-MEXP-1121, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, ... (33 experiments)

Factor Value U/D Experiments
epithelial cell
1
3
E-MEXP-1121, E-MEXP-1327, E-GEOD-10797, E-MEXP-2034
monocyte
1
2
E-GEOD-22373, E-GEOD-995, E-GEOD-11755
spermatid
1
E-TABM-130
germ cell
1
E-MTAB-25
peripheral blood mononuclear cell
1
E-GEOD-3026
primary fibroblast
1
E-MEXP-66
38 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (52 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-GEOD-3726, E-MTAB-62, E-MTAB-57, E-MTAB-37
control
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-20602, E-GEOD-20295
myxoid liposarcoma
2
E-MTAB-62, E-GEOD-6481
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
prostate carcinoma
1
2
E-MTAB-62, E-MEXP-2034, E-MEXP-1327
bladder carcinoma
1
E-TABM-147
192 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-MEXP-2590, ... (17 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-5230, E-GEOD-5824, E-GEOD-412, E-GEOD-7307, E-GEOD-5418, ... (6 experiments)
ethanol
1
E-GEOD-3113
ponasterone A
1
E-GEOD-3113
granulocyte-colony stimulating factor
1
E-GEOD-7400
Cxcl12
1
1
E-GEOD-7307
NaOH
1
E-MEXP-2590
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21374, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-GEOD-4667, E-TABM-145, E-MEXP-958, E-MEXP-1082, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138, E-GEOD-19665, E-GEOD-1751, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-MTAB-108, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-TABM-127, E-GEOD-20540, E-MEXP-1446, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-26, E-TABM-15, ... (29 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657

Pn
studied in E-GEOD-21653

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Qrt pcr areg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-22541

Processing time: 0.412 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM